UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) August 15, 2006
Momenta Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
000-50797 |
|
04-3561634 |
||
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
||
of Incorporation) |
|
|
|
Identification No.) |
||
|
|
|
|
|
||
675 West Kendall Street, Cambridge, MA |
|
02142 |
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||||
(617) 491-9700
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
At the request of the Securities and Exchange Commission, Momenta Pharmaceuticals, Inc. (the Company), hereby files the following exhibit in its entirety, which exhibit was originally filed as Exhibit 10.5 to the Companys Form S-1/A dated May 11, 2004 (File No. 333-113522) (the Original Exhibit). The following exhibit replaces the Original Exhibit in its entirety.
Exhibit No. |
|
Description |
|
|
|
10.1. |
|
Amended and Restated Exclusive Patent License Agreement, dated November 1, 2002, by and between the Massachusetts Institute of Technology and the Registrant (the November 1, 2002 M.I.T. License); First Amendment to the November 1, 2002 M.I.T. License, dated November 15, 2002, by and between the Massachusetts Institute of Technology and the Registrant; Letter Agreement, dated September 12, 2003, between the Massachusetts Institute of Technology and the Registrant; Letter Agreement, dated October 22, 2003, between the Massachusetts Institute of Technology and the Registrant; Second Amendment to the November 1, 2002 M.I.T. License, dated November 19, 2003, by and between the Massachusetts Institute of Technology and the Registrant; Third Amendment to the November 1, 2002 M.I.T. License, dated April 2, 2004, by and between the Massachusetts Institute of Technology and the Registrant. |
Confidential treatment has been granted as to certain portions of this Exhibit. Such portions have been omitted and filed separately with the Securities and Exchange Commission.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
MOMENTA PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
By: |
/s/ Richard P. Shea |
|
|
|
|
|
Richard P. Shea |
|
|
Chief Financial Officer |
|
|
(Principal Financial Officer) |
|
|
|
Date: August 15, 2006 |
|
|
3
EXHIBIT INDEX
Exhibit No. |
|
Description |
10.1. |
|
Amended and Restated Exclusive Patent License Agreement, dated November 1, 2002, by and between the Massachusetts Institute of Technology and the Registrant (the November 1, 2002 M.I.T. License); First Amendment to the November 1, 2002 M.I.T. License, dated November 15, 2002, by and between the Massachusetts Institute of Technology and the Registrant; Letter Agreement, dated September 12, 2003, between the Massachusetts Institute of Technology and the Registrant; Letter Agreement, dated October 22, 2003, between the Massachusetts Institute of Technology and the Registrant; Second Amendment to the November 1, 2002 M.I.T. License, dated November 19, 2003, by and between the Massachusetts Institute of Technology and the Registrant; Third Amendment to the November 1, 2002 M.I.T. License, dated April 2, 2004, by and between the Massachusetts Institute of Technology and the Registrant. |
Confidential treatment has been granted as to certain portions of this Exhibit. Such portions have been omitted and filed separately with the Securities and Exchange Commission.
4